Journal article
Overview and Current Status of Peptide Receptor Radionuclide Therapy
Surgical oncology clinics of North America, Vol.29(2), pp.317-326
04/01/2020
DOI: 10.1016/j.soc.2019.11.005
PMID: 32151363
Abstract
Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits. The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The treatment paradigm typically leads to significant improvement in symptomology coupled with an extended period of progression-free survival. Side effects are limited, with a small fraction of individuals experiencing clinically significant long-term renal or hematologic toxicity.
Details
- Title: Subtitle
- Overview and Current Status of Peptide Receptor Radionuclide Therapy
- Creators
- David L. Bushnell - University of Iowa Hospitals and ClinicsKellie L. Bodeker - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Surgical oncology clinics of North America, Vol.29(2), pp.317-326
- Publisher
- Elsevier
- DOI
- 10.1016/j.soc.2019.11.005
- PMID
- 32151363
- ISSN
- 1055-3207
- eISSN
- 1558-5042
- Number of pages
- 11
- Grant note
- P50 CA174521 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 04/01/2020
- Academic Unit
- Radiology
- Record Identifier
- 9984318799602771
Metrics
12 Record Views